Search HYEX
HEALTHY EXTRACTS INC.
OTC · CIK 1630176
Last close1.05
Daily change+0.00 (0.00%)
10 Years gain-99.99%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
HYEX · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
41.3Momentum
n/aAcceleration
n/aConfidence
71.0Annual Revenue11
Quarterly Revenue44
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth23.5 / 25
Quality15.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.8474 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM70%OK
Revenue CAGR 3Y26.08%OK
Gross Margin62.56%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $4.51M | $2.42M | n/a | $165,520.00 | n/a | 53.69% | n/a | n/a | n/a | n/a |
| 2025 FY Dec 31, 2024 | $3.11M | $1.91M | n/a | $281,968.00 | n/a | 61.39% | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2023 | $2.49M | $1.62M | n/a | -$415,749.00 | n/a | 65.24% | n/a | n/a | n/a | n/a |
| 2023 FY Dec 31, 2022 | $2.25M | $1.37M | n/a | -$390,621.00 | -$398,608.00 | 60.92% | n/a | -17.7% | n/a | n/a |
| 2022 FY Dec 31, 2021 | $1.68M | $695,078.00 | n/a | -$901,298.00 | -$901,298.00 | 41.46% | n/a | -53.76% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $5.56M | sum latest 4 fiscal quarters Revenue | OK | 0001096906-26-001237, 0001096906-25-001864 |
| Revenue Growth TTM | 70% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001096906-26-001237, 0001096906-25-001864 |
| Revenue CAGR 3Y | 26.08% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001096906-26-000515 |
| Revenue CAGR 5Y | 28.27% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001096906-26-000515 |
| Gross Profit CAGR 3Y | 20.88% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001096906-26-000515 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 62.56% | Gross Profit / Revenue | OK | 0001096906-26-001237, 0001096906-25-001864 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001096906-26-001237 |
| Current Ratio | 0.2x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001096906-26-000515 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001096906-26-001237, 0001096906-25-001864 |
| Gross Margin Delta 1Y | +3.85 pp | GrossMargin_current - GrossMargin_prior_year | OK | 0001096906-26-001237, 0001096906-25-001864 |